Tuberculosis is the leading infectious disease responsible for an estimated one and a half
million human deaths each year around the globe. HIV-TB coinfection and rapid increase in …

Cost-effective animal models that accurately reflect the pathological progression of
pulmonary tuberculosis are needed to screen and evaluate novel tuberculosis drugs and …

Tuberculosis is one of the deadliest infectious diseases existing in the world since ancient
times and still possesses serious threat across the globe. Each year the number of cases …

Drug-resistant tuberculosis (TB) poses a significant challenge to the successful treatment
and control of TB worldwide. Resistance to anti-TB drugs has existed since the beginning of …

ABSTRACT PA-824 is a novel antibacterial agent that has shown in vitro activity against
both drug-sensitive and drug-resistant Mycobacterium tuberculosis. The compound's MIC is …

The recent development and spread of extensively drug-resistant and totally drug-resistant
resistant (TDR) strains of Mycobacterium tuberculosis highlight the need for new …

Tuberculosis (TB) remains one of the leading causes of mortality and morbidity worldwide,
with approximately one-third of the world's population infected with latent TB. This is further …

One third of the world population is infected with tuberculosis (TB), and new infections occur
at a rate of one per second. The recent increase in the emergence of drug-resistant strains of …

Latent tuberculosis infection (LTBI) represents a subclinical, asymptomatic mycobacterial
state affecting approximately 25% of the global population. The substantial prevalence of …

Tuberculosis is a major health problem worldwide, with approximately 1.7 million people
dying annually from the disease. The long current drug regimen, the emergence of drug …